Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS

— No overall statistically significant increased risk of bladder cancer in patients ever exposed to pioglitazone in a completed 10-year epidemiological study

OSAKA, Japan, Aug. 29, 2014 /PRNewswire/ — Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the post-marketing commitment and submissions of …

Read More

Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study

— Company To Pursue Next Stage of Development

REDWOOD CITY, California, Aug. 15, 2014  /PRNewswire/ — Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity study that compared …

Read More

Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials

PHILADELPHIA, July 22, 2014 /PRNewswire/ — The Intellectual Property and Science business of Thomson Reuters, the world’s leading provider of intelligent information for businesses and professionals, today announced Cortellis Clinical Trials Intelligence, its global clinical-drug-trial intelligence database, marked an industry-first milestone with …

Read More